Have a feature idea you'd love to see implemented?
Let us know!
AXDX Accelerate Diagnostics Inc
Price (delayed)
$1.67
Market cap
$41.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.64
Enterprise value
$81.11M
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC
Highlights
The quick ratio has soared by 100% YoY and by 40% QoQ
The gross margin rose by 39% QoQ and by 6% YoY
Accelerate Diagnostics's EPS has soared by 56% YoY but it has decreased by 33% from the previous quarter
The company's net income fell by 41% QoQ but it rose by 15% YoY
AXDX's debt has soared by 61% YoY and by 39% QoQ
AXDX's equity is down by 39% QoQ and by 38% YoY
Key stats
What are the main financial stats of AXDX
Market
Valuations
Earnings
Shares outstanding
25.04M
Market cap
$41.82M
Enterprise value
$81.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.81
Revenue
$11.91M
EBIT
-$42.13M
EBITDA
-$38.7M
Free cash flow
-$27.5M
Per share
Balance sheet
Liquidity
EPS
-$2.64
Free cash flow per share
-$1.1
Book value per share
-$2.05
Revenue per share
$0.48
TBVPS
$1.3
Total assets
$32.32M
Total liabilities
$80.8M
Debt
$58.97M
Equity
-$48.48M
Working capital
$9.18M
Debt to equity
-1.22
Current ratio
1.5
Quick ratio
1.26
Net debt/EBITDA
-1.02
Margins
Efficiency
Dividend
EBITDA margin
-324.9%
Gross margin
24.3%
Net margin
-448.9%
Operating margin
-320%
Return on assets
-182.3%
Return on equity
N/A
Return on invested capital
-91.9%
Return on capital employed
-299.7%
Return on sales
-353.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AXDX stock price
How has the Accelerate Diagnostics stock price performed over time
Intraday
-1.76%
1 week
-10.7%
1 month
-9.73%
1 year
-63.77%
YTD
-57.4%
QTD
-2.34%
Financial performance
How have Accelerate Diagnostics's revenue and profit performed over time
Revenue
$11.91M
Gross profit
$2.89M
Operating income
-$38.11M
Net income
-$53.46M
Gross margin
24.3%
Net margin
-448.9%
AXDX's net margin is down by 45% QoQ but it is up by 15% YoY
The company's net income fell by 41% QoQ but it rose by 15% YoY
The gross margin rose by 39% QoQ and by 6% YoY
The gross profit has increased by 35% QoQ and by 4.7% YoY
Growth
What is Accelerate Diagnostics's growth rate over time
Valuation
What is Accelerate Diagnostics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.81
Accelerate Diagnostics's EPS has soared by 56% YoY but it has decreased by 33% from the previous quarter
AXDX's equity is down by 39% QoQ and by 38% YoY
AXDX's price to sales (P/S) is 87% less than its 5-year quarterly average of 26.0 but 20% more than its last 4 quarters average of 2.9
The revenue has declined by 2.6% since the previous quarter
Efficiency
How efficient is Accelerate Diagnostics business performance
Accelerate Diagnostics's return on invested capital has surged by 61% YoY but it has decreased by 22% QoQ
Accelerate Diagnostics's ROS has plunged by 55% from the previous quarter but it has increased by 24% YoY
Accelerate Diagnostics's ROA has decreased by 49% from the previous quarter and by 48% YoY
Dividends
What is AXDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AXDX.
Financial health
How did Accelerate Diagnostics financials performed over time
The company's total assets is 60% lower than its total liabilities
The quick ratio has soared by 100% YoY and by 40% QoQ
The company's current ratio has surged by 74% YoY and by 17% QoQ
AXDX's debt has soared by 61% YoY and by 39% QoQ
AXDX's equity is down by 39% QoQ and by 38% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.